Ethyreal Bio is a biotechnology startup developing precision therapies for autoimmune thyroid disorders.
Ethyreal Bio has raised $60.0M in total funding. The most recent round was Series B. The last funding was announced in January 2026.
Ethyreal Bio's investors include Atlas Venture, Medicxi, Avoro Capital Advisors, Nandi Life Sciences LLC, Checkpoint Capital.
Ethyreal Bio is headquartered in Cambridge, United States.
Ethyreal Bio is a biotechnology startup developing precision therapies for autoimmune thyroid disorders.
Ethyreal Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ethyreal Bio — Funding & Investors." VCBacked, January 1, 2026, https://www.vcbacked.co/company/ethyreal-bio. Accessed September 30, 2026.
VCBacked. (2026). Ethyreal Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/ethyreal-bio
{{cite web |title=Ethyreal Bio — Funding & Investors |url=https://www.vcbacked.co/company/ethyreal-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated